Literature DB >> 17667893

The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.

Jeffrey H Newcorn1, Margaret Weiss, Mark A Stein.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is an impairing but usually treatable condition. Popular culture propagates the myth that ADHD recedes with age; this is not the case. Although it is common, <20% of adults with ADHD are diagnosed or treated. Adults with ADHD show significant comorbidities with depressive disorders, anxiety disorders, substance use, oppositional defiant disorder, personality disorders, sleep problems, and learning disabilities. However, symptoms that result from ADHD, such as mood symptoms or lability, are often mistaken for comorbid disorders. Comorbidity with ADHD impacts treatment compliance, treatment response, and patient insight. Insufficient data on the interaction between ADHD and comorbidities impedes proper diagnosis and treatment. Better clinical tools for assessing these conditions are needed. Food and Drug Administration-approved pharmacologic treatments for adult ADHD include stimulants, dexmethylphenidate, and the nonstimulant atomoxetine. Effect sizes of approved medicines at approved doses are half those seen in children. Adults may also need longer duration of medication effects than children. Short-acting stimulants are likely to result in poorer adherence and have a higher risk for diversion or abuse. Risk of abuse is a major concern; stimulant treatments are controlled substances, and children with ADHD show increased risk of substance abuse. Psychosocial interventions may be beneficial in treating both ADHD and comorbidities.In this expert roundtable supplement, Margaret Weiss, MD, PhD, presents a comprehensive overview of complications surrounding differential diagnosis in adults with ADHD. Next, Mark A. Stein, PhD, reviews evaluation, comorbidity, and development of a treatment plan in this population. Finally, Jeffrey H. Newcorn, MD, provides a discussion on the pharmacologic options available for adults with ADHD, considering dosages specific to adults and common comorbidities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667893     DOI: 10.1017/s1092852900026158

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  13 in total

1.  Adults With Persistent ADHD: Gender and Psychiatric Comorbidities-A Population-Based Longitudinal Study.

Authors:  Kouichi Yoshimasu; William J Barbaresi; Robert C Colligan; Robert G Voigt; Jill M Killian; Amy L Weaver; Slavica K Katusic
Journal:  J Atten Disord       Date:  2016-11-18       Impact factor: 3.256

2.  Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis.

Authors:  Paul Hodgkins; Leslie Montejano; Rahul Sasané; Dan Huse
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 3.  Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.

Authors:  Jose Martinez-Raga; Amparo Ferreros; Carlos Knecht; Raquel de Alvaro; Eloisa Carabal
Journal:  Ther Adv Drug Saf       Date:  2016-11-29

4.  Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.

Authors:  Leo Bastiaens; Olivia Scott; James Galus
Journal:  Psychiatr Q       Date:  2019-03

5.  Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.

Authors:  Katrien De Bruyckere; Chris Bushe; Christoph Bartel; Lovisa Berggren; Cornelis C Kan; Ralf W Dittmann
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

6.  Factors contributing to the utilization of adult mental health services in children and adolescents diagnosed with hyperkinetic disorder.

Authors:  Hilario Blasco-Fontecilla; Juan J Carballo; Rebeca Garcia-Nieto; Jorge Lopez-Castroman; Analucia A Alegria; Ignacio Basurte-Villamor; Juncal Sevilla-Vicente; Rocio Navarro-Jimenez; Teresa Legido-Gil; Consuelo Morant-Ginestar; Miguel Angel Jimenez-Arriero; Jeronimo Saiz-Ruiz; Enrique Baca-Garcia
Journal:  ScientificWorldJournal       Date:  2012-04-30

7.  Methylphenidate off-label use and safety.

Authors:  Thierry Trenque; Emmanuelle Herlem; Malak Abou Taam; Moustapha Drame
Journal:  Springerplus       Date:  2014-06-07

8.  Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature.

Authors:  Ylva Ginsberg; Javier Quintero; Ernie Anand; Marta Casillas; Himanshu P Upadhyaya
Journal:  Prim Care Companion CNS Disord       Date:  2014-06-12

Review 9.  A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.

Authors:  David B Clemow; Chris Bushe; Michele Mancini; Michael H Ossipov; Himanshu Upadhyaya
Journal:  Neuropsychiatr Dis Treat       Date:  2017-02-03       Impact factor: 2.570

10.  Trait Anxiety as a Mediator of the Association between Attention Deficit Hyperactivity Disorder Symptom Severity and Functional Impairment.

Authors:  Yunhye Oh; Hee Joon Yoon; Ji-Hae Kim; Yoo Sook Joung
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-11-30       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.